Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NXTCL.ST
- Price
- 1.07
- Stock movement down
- -0.11 (-9.32%)
- Company name
- NextCell Pharma AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 78.21M
- Ent value
- 45.11M
- Price/Sales
- 7.33
- Price/Book
- 1.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 1.67%
- 1 year return
- -63.85%
- 3 year return
- -48.90%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
NXTCL.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.33 |
| Price to Book | 1.16 |
| EV to Sales | 4.23 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 73.09M |
| EPS (TTM) | -0.70 |
| FCF per share (TTM) | -0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.66M |
| Gross profit (TTM) | -21.51M |
| Operating income (TTM) | -43.20M |
| Net income (TTM) | -41.96M |
| EPS (TTM) | -0.70 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -201.68% |
| Operating margin (TTM) | -405.08% |
| Profit margin (TTM) | -393.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.79M |
| Net receivables | 13.29M |
| Total current assets | 60.62M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 81.29M |
| Accounts payable | 6.16M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 9.87M |
| Total liabilities | 13.69M |
| Shareholder's equity | 67.60M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -37.78M |
| Capital expenditures (TTM) | 82.93K |
| Free cash flow (TTM) | -37.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.07% |
| Return on Assets | -51.62% |
| Return on Invested Capital | -62.07% |
| Cash Return on Invested Capital | -56.01% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.20 |
| Daily high | 1.21 |
| Daily low | 1.02 |
| Daily Volume | 826K |
| All-time high | 29.60 |
| 1y analyst estimate | - |
| Beta | 0.71 |
| EPS (TTM) | -0.70 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NXTCL.ST | S&P500 | |
| Current price drop from All-time high | -96.39% | -12.89% |
| Highest price drop | -96.39% | -56.47% |
| Date of highest drop | 11 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -72.18% | -11.07% |
| Avg time to new high | 170 days | 12 days |
| Max time to new high | 1144 days | 1805 days |
COMPANY DETAILS
Marketcap
78.21M
Marketcap category
Small-cap
Description
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found